Home › Companies › MERSANA THERAPEUTICS INC. › 2023-2024

MERSANA THERAPEUTICS INC. 2023-2024 Proxy Voting Records

Compiled from SEC Form N-PX filings and MERSANA THERAPEUTICS INC.’s Form 8-K, filed June 11, 2024 (Item 5.07 on EDGAR). Page generated October 13, 2026.

4Ballot items
140Asset managers
660Fund votes
June 11, 2024Meeting date

Results at a glance

Meeting of June 11, 2024: 4 items on MERSANA THERAPEUTICS INC.’s Form 8-K, filed June 11, 2024: 2 elected · 2 approved.

Material dissent

None.

Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided · This season’s results screens

Proxy season: 2023-2024

Explore MERSANA THERAPEUTICS INC. in the interactive database Compare manager voting policies

Official 2023-2024 meeting results reported by MERSANA THERAPEUTICS INC.

These tallies are MERSANA THERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 11, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

MERSANA THERAPEUTICS INC. — official shareholder meeting results, meeting held June 11, 2024
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Support (of votes cast)	Reported outcome	Voting standard
Elect Director: Willard H. Dere, M.D.	84,576,414	12,733,786	104,329	--	8,260,872	87%	Elected	—
Elect Director: Martin Huber, M.D.	96,836,592	472,410	105,527	--	8,260,872	99.5%	Elected	—
2. Advisory Vote on Executive Compensation	96,316,340	984,371	113,818	--	8,260,872	99%	Approved	—
3. Ratification of Selection of Independent Registered Public Accounting Firm	105,233,670	323,020	118,711	--	--	99.6%	Approved	—

Source: MERSANA THERAPEUTICS INC., Form 8-K, filed with the SEC on June 11, 2024 — read the filing on EDGAR.

How asset managers voted at the MERSANA THERAPEUTICS INC. 2023-2024 meeting

Each item below shows how the 140 asset managers that disclosed a MERSANA THERAPEUTICS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.

1. Elect Director: Martin Huber, M.D.

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 2 wordings of this item as funds reported it.

99.5% Majority: yes · of votes cast

FOR 99.5%

FOR: 96,836,592AGAINST: 472,410

Details: description as filed, official tally, votes by 42 asset managers

Description as filed by funds: Election of Class I Directors, each to serve until the 2027 Annual Meeting of Stockholders: Martin Huber, M.D.

MERSANA THERAPEUTICS INC.’s own tally for this item (“Elect Director: Martin Huber, M.D.”): 96,836,592 for, 472,410 against, per its Form 8-K filed June 11, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1 - Election of Directors The Company's stockholders elected the two persons listed below as Class I directors, each to serve until the Company's 2027 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified.”
Support: 99.5% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 42 asset managers below reported 19,708,581 for, 14,464 against.

FOR

FOR: 19,708,581AGAINST: 14,464

Largest asset managers voting on “Election of Class I Directors, each to serve until the 2027 Annual Meeting of Stockholders: Martin Huber, M.D.” at MERSANA THERAPEUTICS INC., 2023-2024
Asset manager	For	Against	Vote
Vanguard	6,218,949	0	For
BlackRock	4,058,042	0	For
State Street	3,015,686	4,719	For
Fidelity	2,416,647	0	For
JPMorgan	949,330	0	For
Equitable	351,584	0	For
Direxion Shares ETF Trust	333,424	0	For
Charles Schwab	295,872	0	For
Invesco	291,363	0	For
BRIDGEWAY FUNDS INC	232,300	0	For
SEI	212,020	0	For
Lincoln Financial	168,180	2,209	For
QUANTITATIVE MASTER SERIES LLC	161,956	0	For
Delaware/Macquarie	150,000	0	For
Voya	144,037	0	For
TIAA	117,317	0	For
ProShares	71,514	0	For
ETF Series Solutions	57,347	0	For
AIG/SunAmerica	54,639	0	For
John Hancock	41,953	0	For
Pacific Life	41,846	0	For
FORUM FUNDS II	40,200	0	For
Brighthouse	36,454	0	For
New York Life	29,740	0	For
Nationwide	29,622	0	For

Showing the 25 largest of 42 asset managers. See all 42 in the interactive database.

2. Elect Director: Willard H. Dere, M.D.

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 2 wordings of this item as funds reported it.

87% Majority: yes · of votes cast

FOR 87%

FOR: 84,576,414AGAINST: 12,733,786

Details: description as filed, official tally, votes by 42 asset managers

Description as filed by funds: Election of Class I Directors, each to serve until the 2027 Annual Meeting of Stockholders: Willard H. Dere, M.D.

MERSANA THERAPEUTICS INC.’s own tally for this item (“Elect Director: Willard H. Dere, M.D.”): 84,576,414 for, 12,733,786 against, per its Form 8-K filed June 11, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1 - Election of Directors The Company's stockholders elected the two persons listed below as Class I directors, each to serve until the Company's 2027 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified.”
Support: 87% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 42 asset managers below reported 17,894,798 for, 1,828,247 against.

FOR

FOR: 17,894,798AGAINST: 1,828,247

Largest asset managers voting on “Election of Class I Directors, each to serve until the 2027 Annual Meeting of Stockholders: Willard H. Dere, M” at MERSANA THERAPEUTICS INC., 2023-2024
Asset manager	For	Against	Vote
Vanguard	6,207,238	11,711	For
BlackRock	4,058,042	0	For
State Street	2,976,654	43,751	For
Fidelity	2,405,947	10,700	For
JPMorgan	949,330	0	For
Equitable	182,774	168,810	Mixed
Direxion Shares ETF Trust	0	333,424	Against
Charles Schwab	295,872	0	For
Invesco	0	291,363	Against
BRIDGEWAY FUNDS INC	0	232,300	Against
SEI	212,020	0	For
Lincoln Financial	168,180	2,209	For
QUANTITATIVE MASTER SERIES LLC	161,956	0	For
Delaware/Macquarie	0	150,000	Against
Voya	0	144,037	Against
TIAA	117,317	0	For
ProShares	0	71,514	Against
ETF Series Solutions	0	57,347	Against
AIG/SunAmerica	0	54,639	Against
John Hancock	0	41,953	Against
Pacific Life	41,846	0	For
FORUM FUNDS II	0	40,200	Against
Brighthouse	0	36,454	Against
New York Life	29,740	0	For
Nationwide	1,065	28,557	Against

Showing the 25 largest of 42 asset managers. See all 42 in the interactive database.

3. 2. Advisory Vote on Executive Compensation

Official result Fund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Approved

Combines 7 wordings of this item as funds reported it.

99% Approved · of votes cast

FOR 99%

FOR: 96,316,340AGAINST: 984,371

Details: description as filed, official tally, votes by 140 asset managers

Description as filed by funds: To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers.

MERSANA THERAPEUTICS INC.’s own tally for this item (“2. Advisory Vote on Executive Compensation”): 96,316,340 for, 984,371 against — passed, per its Form 8-K filed June 11, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 2 – Advisory Vote on Executive Compensation The Company's stockholders approved Proposal 2.”
Support: 99% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 42 asset managers voting on “To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers.” at MERSANA THERAPEUTICS INC., 2023-2024
Asset manager	For	Against	Vote
Vanguard	6,218,949	0	For
BlackRock	4,058,042	0	For
State Street	3,020,405	0	For
Fidelity	2,416,647	0	For
JPMorgan	949,330	0	For
Equitable	351,584	0	For
Direxion Shares ETF Trust	333,424	0	For
Charles Schwab	295,872	0	For
Invesco	0	291,363	Against
BRIDGEWAY FUNDS INC	232,300	0	For
SEI	212,020	0	For
Lincoln Financial	170,389	0	For
QUANTITATIVE MASTER SERIES LLC	161,956	0	For
Delaware/Macquarie	150,000	0	For
Voya	144,037	0	For
TIAA	117,317	0	For
ProShares	71,514	0	For
ETF Series Solutions	57,347	0	For
AIG/SunAmerica	54,639	0	For
John Hancock	41,953	0	For
Pacific Life	41,846	0	For
FORUM FUNDS II	40,200	0	For
Brighthouse	36,454	0	For
New York Life	29,740	0	For
Nationwide	29,622	0	For

Fund voting reports, all 42 managers: 19,421,786 for, 301,259 against. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports: 112 asset managers voting on “To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers.” at MERSANA THERAPEUTICS INC., 2023-2024
Asset manager	For	Against	Vote
EcoR1 Capital, LLC	19,364,688	0	For
VR Adviser, LLC	11,328,000	0	For
Bain Capital Life Sciences Investors, LLC	8,663,673	0	For
State Street	5,229,182	0	For
BlackRock	3,491,446	0	For
Rock Springs Capital Management LP	3,046,782	0	For
Woodline Partners LP	2,934,622	0	For
Citadel	2,642,768	0	For
GEODE CAPITAL MANAGEMENT, LLC	2,346,362	0	For
SILVERARC CAPITAL MANAGEMENT, LLC	2,196,111	0	For
Cormorant Asset Management, LP	1,863,681	0	For
BALYASNY ASSET MANAGEMENT L.P.	1,444,981	0	For
5AM Venture Management, LLC	1,305,000	0	For
DE Shaw	1,278,087	0	For
Octagon Capital Advisors LP	1,000,000	0	For
Northern Trust	835,343	93	For
JACOBS LEVY EQUITY MANAGEMENT, INC	767,907	0	For
Affinity Asset Advisors, LLC	750,000	0	For
MELLON INVESTMENTS Corp	548,746	0	For
Wellington	483,640	0	For
UBS	434,293	0	For
PNC BANK, NATIONAL ASSOCIATION	414,200	0	For
Renaissance	388,639	0	For
Verition Fund Management LLC	358,124	0	For
Rafferty Asset Management, LLC	333,424	0	For

Institutional-manager reports, all 112 managers: 77,361,040 for, 679,546 against, 71,572 abstained, 28 unknown. Showing the 25 largest; see all in the interactive database.

4. 3. Ratification of Selection of Independent Registered Public Accounting Firm

Official resultAUDIT-RELATEDReported outcome: Approved

Combines 2 wordings of this item as funds reported it.

99.6% Approved · of votes cast

FOR 99.6%

FOR: 105,233,670AGAINST: 323,020

Details: description as filed, official tally, votes by 42 asset managers

Description as filed by funds: To ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024.

MERSANA THERAPEUTICS INC.’s own tally for this item (“3. Ratification of Selection of Independent Registered Public Accounting Firm”): 105,233,670 for, 323,020 against — passed, per its Form 8-K filed June 11, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 3 – Ratification of Selection of Independent Registered Public Accounting Firm The Company's stockholders approved Proposal 3.”
Support: 99.6% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 42 asset managers below reported 19,717,879 for, 5,166 against.

FOR

FOR: 19,717,879AGAINST: 5,166

Largest asset managers voting on “To ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm fo” at MERSANA THERAPEUTICS INC., 2023-2024
Asset manager	For	Against	Vote
Vanguard	6,218,949	0	For
BlackRock	4,058,042	0	For
State Street	3,015,239	5,166	For
Fidelity	2,416,647	0	For
JPMorgan	949,330	0	For
Equitable	351,584	0	For
Direxion Shares ETF Trust	333,424	0	For
Charles Schwab	295,872	0	For
Invesco	291,363	0	For
BRIDGEWAY FUNDS INC	232,300	0	For
SEI	212,020	0	For
Lincoln Financial	170,389	0	For
QUANTITATIVE MASTER SERIES LLC	161,956	0	For
Delaware/Macquarie	150,000	0	For
Voya	144,037	0	For
TIAA	117,317	0	For
ProShares	71,514	0	For
ETF Series Solutions	57,347	0	For
AIG/SunAmerica	54,639	0	For
John Hancock	41,953	0	For
Pacific Life	41,846	0	For
FORUM FUNDS II	40,200	0	For
Brighthouse	36,454	0	For
New York Life	29,740	0	For
Nationwide	29,622	0	For

Showing the 25 largest of 42 asset managers. See all 42 in the interactive database.

Largest MERSANA THERAPEUTICS INC. shareholders voting in 2023-2024

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 122,361,236 shares outstanding at the time of that meeting.

Fund voting reports: top MERSANA THERAPEUTICS INC. shareholders by shares voted on “To approve, on a non-binding, advisory basis, the compensation of the Company's named executive…”, 2023-2024
#	Asset manager	% of shares outstanding
1	Vanguard	5.08%
2	BlackRock	3.32%
3	State Street	2.47%
4	Fidelity	1.98%
5	JPMorgan	0.78%
6	Equitable	0.29%
7	Direxion Shares ETF Trust	0.27%
8	Charles Schwab	0.24%
9	Invesco	0.24%
10	BRIDGEWAY FUNDS INC	0.19%

Institutional-manager reports: top MERSANA THERAPEUTICS INC. shareholders by shares voted on “To approve, on a non-binding, advisory basis, the compensation of the Company's named executive…”, 2023-2024
#	Asset manager	% of shares outstanding
1	EcoR1 Capital, LLC	15.83%
2	VR Adviser, LLC	9.26%
3	Bain Capital Life Sciences Investors, LLC	7.08%
4	State Street	4.27%
5	BlackRock	2.85%
6	Rock Springs Capital Management LP	2.49%
7	Woodline Partners LP	2.40%
8	Citadel	2.16%
9	GEODE CAPITAL MANAGEMENT, LLC	1.92%
10	SILVERARC CAPITAL MANAGEMENT, LLC	1.79%

Reported MERSANA THERAPEUTICS INC. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.

MERSANA THERAPEUTICS INC. holdings and ownership disclosed for the 2023-2024 proxy season
Holder	% outstanding	Disclosure
Entities affiliated with EcoR1 Capital, LLC	15.83%	DEF14A
Nextech Crossover I SCSp	9.86%	13G
Entities affiliated with Venrock Healthcare Capital Partners III, L.P.	9.26%	DEF14A
Entities affiliated with Balyasny Asset Management L.P.	7.93%	DEF14A
Andrew A. F. Hack, M.D., Ph.D.	7.25%	DEF14A
Entities affiliated with Bain Capital Life Sciences	7.08%	DEF14A
Blackrock, Inc.	6.41%	DEF14A
SilverArc Capital Management, LLC	5.25%	DEF14A
The Vanguard Group	5.10%	13G
State Street	4.49%	13F

Percentages above are of 122,361,236 shares outstanding, as reported by MERSANA THERAPEUTICS INC. on its Form 10-Q dated May 3, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from MERSANA THERAPEUTICS INC.’s 10-Q dated May 3, 2024. This page is a static snapshot rebuilt weekly on October 13, 2026; a live search always shows the current data.

At MERSANA THERAPEUTICS INC.'s shareholder meeting held June 11, 2024, in the 2023-2024 proxy season, 140 asset managers reported how they voted on 4 ballot items in their SEC Form N-PX filings, covering 660 separate fund positions. On the most widely held item on that ballot — To approve, on a non-binding, advisory basis, the compensation of the Company's named executive… — MERSANA THERAPEUTICS INC.'s filing reports the proposal as approved, with 99% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: MERSANA THERAPEUTICS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 11, 2024.

MERSANA THERAPEUTICS INC. proxy season coverage: 2023-2024 (this page).

Download data (CSV): ballot items · votes by manager · column guide.